基于纳米技术的结核病治疗方法

Tuberculosis Research and Treatment Pub Date : 2017-01-01 Epub Date: 2017-01-22 DOI:10.1155/2017/4920209
Mohammad Nasiruddin, Md Kausar Neyaz, Shilpi Das
{"title":"基于纳米技术的结核病治疗方法","authors":"Mohammad Nasiruddin, Md Kausar Neyaz, Shilpi Das","doi":"10.1155/2017/4920209","DOIUrl":null,"url":null,"abstract":"<p><p>Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called <i>Mycobacterium tuberculosis</i>. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis. Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment. Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which still remains a major challenge for pharmaceutical technology. Nanoparticle-based ideology has shown convincing treatment and promising outcomes for chronic infectious diseases. Different types of nanocarriers have been evaluated as promising drug delivery systems for various administration routes. Controlled and sustained release of drugs is one of the advantages of nanoparticle-based antituberculosis drugs over free drug. It also reduces the dosage frequency and resolves the difficulty of low poor compliance. This paper reviews various nanotechnology-based therapies which can be used for the treatment of TB.</p>","PeriodicalId":30261,"journal":{"name":"Tuberculosis Research and Treatment","volume":" ","pages":"4920209"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292193/pdf/","citationCount":"0","resultStr":"{\"title\":\"Nanotechnology-Based Approach in Tuberculosis Treatment.\",\"authors\":\"Mohammad Nasiruddin, Md Kausar Neyaz, Shilpi Das\",\"doi\":\"10.1155/2017/4920209\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called <i>Mycobacterium tuberculosis</i>. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis. Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment. Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which still remains a major challenge for pharmaceutical technology. Nanoparticle-based ideology has shown convincing treatment and promising outcomes for chronic infectious diseases. Different types of nanocarriers have been evaluated as promising drug delivery systems for various administration routes. Controlled and sustained release of drugs is one of the advantages of nanoparticle-based antituberculosis drugs over free drug. It also reduces the dosage frequency and resolves the difficulty of low poor compliance. This paper reviews various nanotechnology-based therapies which can be used for the treatment of TB.</p>\",\"PeriodicalId\":30261,\"journal\":{\"name\":\"Tuberculosis Research and Treatment\",\"volume\":\" \",\"pages\":\"4920209\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292193/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tuberculosis Research and Treatment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2017/4920209\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/1/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberculosis Research and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2017/4920209","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/22 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

结核病,俗称TB,是仅次于艾滋病的第二大致命传染病,由结核分枝杆菌引起。长期治疗、高药物负担、低依从性和严格的给药时间表是导致耐多药结核病和广泛耐药结核病病例出现的因素。到目前为止,只有BCG疫苗对成人肺结核无效,而成人肺结核是最常见的疾病。已经开发出各种独特的抗体来克服耐药性,减少治疗方案,提高治疗依从性。因此,我们需要一个有效和稳健的系统来克服技术缺陷,提高治疗药物的有效性,这仍然是制药技术面临的重大挑战。基于纳米粒子的思想已经显示出令人信服的慢性传染病治疗方法和有希望的结果。不同类型的纳米载体已被评估为用于各种给药途径的有前途的药物递送系统。药物的控制和持续释放是纳米颗粒抗结核药物相对于游离药物的优势之一。它还降低了给药频率,解决了依从性差的问题。本文综述了可用于治疗结核病的各种基于纳米技术的疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Nanotechnology-Based Approach in Tuberculosis Treatment.

Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis. Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment. Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which still remains a major challenge for pharmaceutical technology. Nanoparticle-based ideology has shown convincing treatment and promising outcomes for chronic infectious diseases. Different types of nanocarriers have been evaluated as promising drug delivery systems for various administration routes. Controlled and sustained release of drugs is one of the advantages of nanoparticle-based antituberculosis drugs over free drug. It also reduces the dosage frequency and resolves the difficulty of low poor compliance. This paper reviews various nanotechnology-based therapies which can be used for the treatment of TB.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
6
审稿时长
17 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信